This site is intended for healthcare professionals
lung tissue with fibrosis, cell image, blue overlay

Idiopathic pulmonary fibrosis

Last updated: 5th Dec 2025

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease that causes irreversible scarring (fibrosis) and impairs lung function. Most patients present with exertional dyspnea and a persistent dry cough. Without treatment, IPF has a poor prognosis, with a median survival of 3–5 years from diagnosis.

 

What causes IPF?

The exact cause of IPF is unknown. Evidence suggests that repeated injury to the alveolar epithelium and abnormal repair processes drive fibrosis. Genetic predisposition, such as MUC5B promoter polymorphism and telomerase mutations, increases susceptibility, while environmental exposures, including smoking, air pollution, and microaspiration, also play a role.

 

What are the symptoms of IPF?

Patients with IPF commonly report:

  • Progressive exertional dyspnea
  • Dry cough
  • Fatigue

Clinicians often detect fine inspiratory crackles and digital clubbing during physical examination. Pulmonary function tests typically reveal a restrictive pattern and reduced diffusing capacity for carbon monoxide.

 

How is IPF diagnosed?

Diagnosing IPF involves:

  • Reviewing the patient’s clinical history
  • Confirming a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT)
  • Ruling out other causes, such as connective tissue disease (e.g., rheumatoid arthritis, rashes, skin changes) or environmental exposures

If imaging is inconclusive, consider lung biopsy.

A multidisciplinary review involving pulmonologists, radiologists, and pathologists is recommended to confirm the diagnosis.

Pulmonary function tests help monitor disease progression and response to therapy.

What are the treatment options for IPF?

Management of IPF includes antifibrotic agents, such as nintedanib and pirfenidone, which slow disease progression. Supportive care includes:

  • Oxygen therapy
  • Pulmonary rehabilitation
  • Management of comorbidities

Lung transplantation may be considered for eligible patients.

Developed by EPG Health for Medthority, independently of any sponsor.

Welcome:

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.